Press Releases
Dec 9, 2024
COTA Inc., a leader in real-world data (RWD) and analytics for oncology, PreciseDx, an innovator in AI-powered digital pathology focused on oncology diagnostics, and Baptist Health South Florida today announced new study results validating the artificial intelligence (AI)-enabled PreciseBreast™ test is equivalent to the Oncotype DX test at predicting breast cancer recurrence.
See More
Dec 9, 2024
COTA Inc., a leader in real-world data (RWD) and analytics for oncology, PreciseDx, an innovator in AI-powered digital pathology focused on oncology diagnostics, and Baptist Health South Florida today announced new study results validating the artificial intelligence (AI)-enabled PreciseBreast™ test is equivalent to the Oncotype DX test at predicting breast cancer recurrence.
See More
Press Releases
Dec 6, 2024
A study from PreciseDx showed that its artificial-intelligence-guided pathology test could help predict a patient’s chances of their breast cancer returning on par with a leading genomic approach.
See More
Dec 6, 2024
A study from PreciseDx showed that its artificial-intelligence-guided pathology test could help predict a patient’s chances of their breast cancer returning on par with a leading genomic approach.
See More
Press Releases
Nov 20, 2024
World-Renowned Breast Cancer Oncology and Pathology Experts to Advise Company on the Advancement of its AI-Powered PreciseBreastTM Risk of Recurrence Assessment and Product Portfolio
See More
Nov 20, 2024
World-Renowned Breast Cancer Oncology and Pathology Experts to Advise Company on the Advancement of its AI-Powered PreciseBreastTM Risk of Recurrence Assessment and Product Portfolio
See More
Media Coverage
Aug 22, 2024
Start-up raises US$20.7m to ‘advance’ AI-based cancer risk assessments
See More
Aug 22, 2024
Start-up raises US$20.7m to ‘advance’ AI-based cancer risk assessments
See More
Media Coverage
Aug 22, 2024
PreciseDx Raises $20.7M Series B
See More
Aug 22, 2024
PreciseDx Raises $20.7M Series B
See More
Media Coverage
Aug 22, 2024
PreciseDx raises $20.7M in series B funding
See More
Aug 22, 2024
PreciseDx raises $20.7M in series B funding
See More
Media Coverage
Aug 21, 2024
PreciseDx Raises $20.7M in Series B Round
See More
Aug 21, 2024
PreciseDx Raises $20.7M in Series B Round
See More
Media Coverage
Aug 21, 2024
PreciseDx Raises $20.7M for AI-Powered Cancer Risk Assessments
See More
Aug 21, 2024
PreciseDx Raises $20.7M for AI-Powered Cancer Risk Assessments
See More
No results.
Contact us today to learn more about PreciseBreast.
